Valuation: OnKure Therapeutics, Inc.

Market Cap 103M 91.36M 85.44M 77.86M 147M 9.9B 149M 1.03B 400M 5.04B 386M 378M 16.2B P/E 2026 *
-1.39x
P/E 2027 * -1.66x
Enterprise Value 103M 91.36M 85.44M 77.86M 147M 9.9B 149M 1.03B 400M 5.04B 386M 378M 16.2B EV / Sales 2026 *
411x
EV / Sales 2027 * 154x
Free-Float
89.55%
Yield 2026 *
-
Yield 2027 * -
1 day-6.79%
1 week-13.31%
Current month-6.79%
1 month-28.65%
3 months-43.05%
6 months-37.59%
Current year-12.41%
1 week 2.47
Extreme 2.47
2.88
1 month 2.47
Extreme 2.47
3.9
Current year 2.23
Extreme 2.23
5.38
1 year 2.23
Extreme 2.23
5.38
3 years 1.7
Extreme 1.7
20
5 years 1.7
Extreme 1.7
20
10 years 1.7
Extreme 1.7
20
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 A Sell

Chief Financial Officer

-302 0.0007%
9/21/26 A Sell

Chief Executive Officer

-87 0.0002%
8/7/26 A Free

Director

22,350 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
-6.79%-13.31%-4.87% - 103M
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.43%-1.80%+24.10%+77.73% 59.26B
+1.28%-0.11%+4.83%+35.22% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -1.16%-1.80%+47.08%+154.10% 39.25B
Weighted average by Cap. +0.00%-0.32%+58.01%+145.77%

Financials

2026 *2027 *
Net sales 250K 222K 208K 189K 356K 24.07M 361K 2.51M 972K 12.26M 939K 918K 39.37M 667K 592K 554K 505K 950K 64.19M 963K 6.7M 2.59M 32.69M 2.5M 2.45M 105M
Net income -64.23M -57.05M -53.35M -48.62M -91.53M -6.18B -92.79M -645M -250M -3.15B -241M -236M -10.12B -70.41M -62.54M -58.48M -53.29M -100M -6.78B -102M -707M -274M -3.45B -264M -259M -11.09B
Net Debt - -
Logo OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Employees
45
Date Price Change Volume
01/10/26 $2.540 -6.79% 2,082,157
30/09/26 $2.725 +4.81% 831,407
29/09/26 $2.600 -5.80% 339,834
28/09/26 $2.760 -4.83% 442,229
25/09/26 $2.900 -1.02% 91,431
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.540USD
Average target price
15.50USD
Spread / Average Target
+510.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OKUR Stock